Intelligence Feed event · Equity · 2026-10-04

    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial

    Question

    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial

    Direct answer

    Genmab published Phase 2 data from its RAINFOL-01 study evaluating rinatabart sesutecan (Rina-S), an antibody-drug conjugate targeting platinum-resistant ovarian cancer. The treatment yielded a 45.9% objective response rate, 12.1-month median duration of response, and 9.5 months of median progression-free survival across the evaluated cohort.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-orr-in-phase-2-platinum-resistant-ovarian-cancer-trial-9f84d9

    EQUITY
    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
    Genmab published Phase 2 data from its RAINFOL-01 study evaluating rinatabart sesutecan (Rina-S), an antibody-drug conjugate targeting platinum-resistant ovarian cancer. The treatment yielded a 45.9% objective response rate, 12.1-month median duration of response, and 9.5 months of median progression-free survival across the evaluated cohort.
    GMAB
    Impact
    70
    OCT 4
    SIG
    88%
    GMAB
    Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial
    Genmab published Phase 2 data from its RAINFOL-01 study evaluating rinatabart sesutecan (Rina-S), an antibody-drug conjugate targeting platinum-resistant ovarian cancer. The treatment yielded a 45.9% objective response rate, 12.1-month median duration of response, and 9.5 months of median progression-free survival across the evaluated cohort.
    → A 45.9% objective response rate in platinum-resistant ovarian cancer establishes clinical de-risking for Rina-S, impacting Genmab's oncology pipeline enterprise value.
    Impact
    Genmab published Phase 2 data from its RAINFOL-01 study evaluating rinatabart sesutecan (Rina-S), an antibody-drug conjugate targeting platinum-resistant ovarian cancer. The treatment yielded a 45.9% objective response rate, 12.1-month median duration of response, and 9.5 months of median progression-free survival across the evaluated cohort.
    Affected
    GMAB
    Transmission
    A 45.9% objective response rate in platinum-resistant ovarian cancer establishes clinical de-risking for Rina-S, impacting Genmab's oncology pipeline enterprise value.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABbiotech pipeline valuation expansion on positive Phase 2 trial readoutUp1-4w45.9% ORR and 9.5 months mPFS in platinum-resistant ovarian cancer de-risks Rina-S asset.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month